Background
If unaware, the title is a quote from Yogi Berra, that great baseball player and common-man philosopher. So, when the U.S. Court of Appeals affirmed the decision of the U.S. District Court for the district of Nevada and ruled Amarin’s (AMRN) patents for Vascepa obvious and, thus, invalid, it seemed to perfectly capture the moment for the company. As was stated by one observer, “the court’s decision paved the way for Amarin's multi-year exclusive selling window to vanish overnight” and with it the expectation of Vascepa becoming a blockbuster drug.